Table 1 Comparative demographics between chemoresistant and platinium sensitive patients
From: Surgical peritoneal stress creates a pro-metastatic niche promoting resistance to apoptosis via IL-8
Platinium resistant subgroup (n = 16) | Platinium sensitive subgroup (n = 12) | p-value | |
|---|---|---|---|
Age (years) | 60.4 (± 12.1) | 63.8 (± 6.6) | 0.38 |
BMI | 24.1 (± 4.6) | 23.8 (± 3.2) | 0.82 |
CA 125 (U/ml) at baseline | 2600 (± 3098.2) | 1235 (± 1252.0) | 0.16 |
Histological type | |||
Serous | 87.5% (n = 14) | 66.7% (n = 8) | 0.58 |
Undifferentiated | 6.25% (n = 1) | 16.7% (n = 2) | |
Mucinous | 0 | 8.3% (n = 1) | |
Endometrioid | 6.25% (n = 1) | 8.3% (n = 1) | |
FIGO stage | |||
IIIC | 81.2% (n = 13) | 100% (n = 12) | 0.11 |
IV | 18.8% (n = 3) | 0 | |
Count of NAC courses | 4 (3–6) | 3 (3–7) | 0.34 |
Total count of chemotherapy courses | 7 (3–12) | 6 (3–9) | 0.15 |
Delay between diagnosis and surgical debulking (months) | 4.3 (± 1.2) | 3.9 (± 1.2) | 0.43 |
Completeness of cytoreduction scorea | |||
CC-0 | 68.7% (n = 11) | 83.4% (n = 10) | 0.38 |
CC-1 | 6.3% (n = 1) | 0 | |
CC-2 | 18.7% (n = 3) | 8.3% (n = 1) | |
CC-3 | 6.3% (n = 1) | 8.3% (n = 1) | |
Mean IL8 expression on tumor sample | 31.3% | 11.0% | 0.004** |
Duration of surgical procedure (min) | 428 (± 139) | 310 (± 82) | 0.07 |
Overall survival (months) | 31.9 | 78.9 | < 10−4*** |